Role of four and a half LIM domain protein 1 in tumors (Review)
- Authors:
- Yun Tao
- Yaxun Wu
- Rong Shen
- Song He
- Xiaobing Miao
-
Affiliations: Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China - Published online on: October 29, 2024 https://doi.org/10.3892/ol.2024.14783
- Article Number: 37
-
Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Han S, Cui C, He H, Shen X, Chen Y, Wang Y, Li D, Zhu Q and Yin H: FHL1 regulates myoblast differentiation and autophagy through its interaction with LC3. J Cell Physiol. 235:4667–4678. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Liu J, Xia R, Lin L, Wang X, Xiao M, Zhang C, Li J, Ji T and Chen W: X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma. Oncotarget. 7:14537–14550. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wang C, Cheng P, Zhang S, Zhou W, Xu Y, Xu H and Ji G: FHL1 inhibits the progression of colorectal cancer by regulating the Wnt/β-catenin signaling pathway. J Cancer. 12:5345–5354. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Keßler M, Kieltsch A, Kayvanpour E, Katus HA, Schoser B, Schessl J, Just S and Rottbauer W: A zebrafish model for FHL1-opathy reveals Loss-of-function effects of human FHL1 mutations. Neuromuscul Disord. 28:521–531. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li SZ, Hu YY, Zhao JL, Zang J, Fei Z, Han H and Qin HY: Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling. Oncol Lett. 19:3781–3788. 2020.PubMed/NCBI | |
|
Ding J, Cong Y, Li F, Liu B, Wu D, Miao J and Wang L: Muscle death participates in myofibrillar abnormalities in FHL1 knockout mice. Biochem Biophys Res Commun. 523:105–111. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Weng J, Liao M, Zou S, Bao J, Zhou J, Qu L, Feng R, Feng X, Zhao Z and Jing Z: Downregulation of FHL1 expression in thoracic aortic dissection: Implications in aortic wall remodeling and pathogenesis of thoracic aortic dissection. Ann Vasc Surg. 25:240–247. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SMY, Tsui SKW, Chan KK, Garcia-Barcelo M, Waye MM, Fung KP, Liew CC and Lee CY: Chromosomal mapping, tissue distribution and cDNA sequence of Four-and-a-half LIM domain protein 1 (FHL1). Gene. 216:163–170. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Wilding BR, McGrath MJ, Bonne G and Mitchell CA: FHL1 mutations that cause clinically distinct human myopathies form protein aggregates and impair myoblast differentiation. J Cell Sci. 127:2269–2281. 2014.PubMed/NCBI | |
|
Wei X and Zhang H: Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression. Cancer Biol Med. 17:270–281. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Selcen D, Bromberg MB, Chin SS and Engel AG: Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology. 77:1951–1959. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Isumi Y, Hirata T, Saitoh H, Miyakawa T, Murakami K, Kudoh G, Doi H, Ishibashi K and Nakajima H: Transgenic overexpression of USP15 in the heart induces cardiac remodeling in mice. Biochem Biophys Res Commun. 405:216–221. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shathasivam T, Kislinger T and Gramolini AO: Genes, proteins and complexes: The multifaceted nature of FHL family proteins in diverse tissues. J Cell Mol Med. 14:2702–2720. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nishikawa M, Sato K, Nakano S, Yamakawa H, Nagase T and Ueda H: Specific activation of PLEKHG2-induced serum response element-dependent gene transcription by four-and-a-half LIM domains (FHL) 1, but not FHL2 or FHL3. Small GTPases. 10:361–366. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zabalegui F, Castañeda SL, Amin G, Belli C, Miriuka SG and Moro LN: Derivation of two human induced pluripotent stem cell lines carrying a missense mutation in FHL1 (c.377G > A, p.C126Y) linked to familial muscular dystrophy. Stem Cell Res. 75:1033072024. View Article : Google Scholar : PubMed/NCBI | |
|
López Blázquez M, Fernández Ávila AI, Álvarez García-Rovés R, Centeno Jiménez M, Gómez González C and Espinosa Castro MÁ: Description of a novel variant in the FHL1 gene associated with hypertrophic cardiomyopathy with early and aggressive presentation. Rev Esp Cardiol (Engl Ed). 75:968–970. 2022.PubMed/NCBI | |
|
Albrecht I, Wick C, Hallgren Å, Tjärnlund A, Nagaraju K, Andrade F, Thompson K, Coley W, Phadke A, Diaz-Gallo LM, et al: Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest. 125:4612–4624. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Martin DE, Soulard A and Hall MN: TOR regulates ribosomal protein gene expression via PKA and the forkhead transcription factor FHL1. Cell. 119:969–979. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ng WH, Liu X, Ling ZL, Santos CNO, Magalhães LS, Kueh AJ, Herold MJ, Taylor A, Freitas JR, Koit S, et al: FHL1 promotes chikungunya and o'nyong-nyong virus infection and pathogenesis with implications for alphavirus vaccine design. Nat Commun. 14:66052023. View Article : Google Scholar : PubMed/NCBI | |
|
Meertens L, Hafirassou ML, Couderc T, Bonnet-Madin L, Kril V, Kümmerer BM, Labeau A, Brugier A, Simon-Loriere E, Burlaud-Gaillard J, et al: FHL1 is a major host factor for chikungunya virus infection. Nature. 574:259–263. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Meertens L, Hafirassou ML, Couderc T, Bonnet-Madin L, Kril V, Kümmerer BM, Labeau A, Brugier A, Simon-Loriere E, Burlaud-Gaillard J, et al: FHL1 is a key player of chikungunya virus tropism and pathogenesis. C R Biol. 343:79–89. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mota IA, Correia CdC, Fontana PN and Carvalho AAS: Reducing body myopathy-A new pathogenic FHL1 variant and literature review. Neuromuscul Disord. 31:847–853. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Binder MS, Brown E, Aversano T, Wagner KR, Calkins H and Barth AS: Novel FHL1 mutation associated with hypertrophic cardiomyopathy, sudden cardiac death, and myopathy. JACC Case Rep. 2:372–377. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, Hirakawa K and Mori M: Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol. 15:2293–2300. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira CM, de Carvalho AC, da Silva FR, Melendez ME, Lessa RC, Andrade VCC, Kowalski LP, Vettore AL and Carvalho AL: In vitro and in silico validation of CA3 and FHL1 downregulation in oral cancer. BMC Cancer. 18:1932018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Zhang J, Yang B, Li R, Jin L, Wang Z, Yu H, Liu C, Mao Y and You Q: Long intergenic noncoding RNA 00261 acts as a tumor suppressor in non-small cell lung cancer via regulating miR-105/FHL1 axis. J Cancer. 10:6414–6421. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Qian C, Chen T, Zang X and Huang T: MiR-96-5p facilitates lung adenocarcinoma cell phenotypes by inhibiting FHL1. Comput Math Methods Med. 2022:78912222022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Su Q and Li C: Identidication of novel biomarkers in Non-small cell lung cancer using machine learning. Sci Rep. 12:166932022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Lai X, Zhu Y, Huang H, Zeng L and Zhang L: Quantitative proteomics identified circulating biomarkers in lung adenocarcinoma diagnosis. Clin Proteomics. 19:442022. View Article : Google Scholar : PubMed/NCBI | |
|
Song J, Liang K, Wei T, Li L, Huang Z, Chen G, Mao N and Yang J: Expression and predictive significance of FHL1 and SLIT3 in surgically resected lung adenocarcinoma. Comb Chem High Throughput Screen. 26:2226–2237. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Yang F, Lian M, Ma H, Feng L, Shen X, Chen J and Fang J: Identification of key genes associated with papillary thyroid microcarcinoma characteristics by integrating transcriptome sequencing and weighted gene co-expression network analysis. Gene. 811:1460862022. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zeng Qa, Qiu J, Pang T, Ye F, Huang L and Zhang X: MiR-183-5p promotes proliferation, metastasis and angiogenesis in breast cancer cells through negatively regulating four and a Half LIM protein 1. J Breast Cancer. 23:355–372. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Fu J, Jiang M, Zhang X, Cheng L, Xu X, Fan Z, Zhang J, Ye Q and Song H: MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a Direct/Indirect mechanism. PLoS One. 9:e1087082014. View Article : Google Scholar : PubMed/NCBI | |
|
Ji C, Liu H, Xiang M, Liu J, Yue F, Wang W and Chu X: Deregulation of decorin and FHL1 are associated with esophageal squamous cell carcinoma progression and poor prognosis. Int J Clin Exp Med. 8:20965–20970. 2015.PubMed/NCBI | |
|
Eshibona N, Giwa A, Rossouw SC, Gamieldien J, Christoffels A and Bendou H: Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation. Leuk Lymphoma. 63:1897–1906. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Hu X, Liu S, He Y, Lyu L and Jiang L: Clinical value screening, prognostic significance, and key gene identification of TrkB in laryngeal carcinoma. Dis Markers. 2022:13540052022.PubMed/NCBI | |
|
Das K, Chan XB, Epstein D, Te Teh B, Kim KM, Kim ST, Park SH, Kang WK, Rozen S, Lee J and Tan P: NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open. 1:e0000092016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu1 P, Ma Q, Chen H, Zhang L and Zhang X: Identification of RHOBTB2 aberration as an independent prognostic indicator in acute myeloid leukemia. Aging (Albany NY). 13:15269–15284. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Li H, Zhao Y, Li D, Zhang Q, Fu J and Fan S: Targeting FHL1 impairs cell proliferation and differentiation of acute myeloid leukemia cells. Biochem Cell Biol. 100:301–308. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Q, Pan Y, Fu Q, Zhang X, Zhou S, Yu P, Tian H, Liu P, Chen S, Zhang H and Qin T: Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity. Cell Biol Toxicol. 39:2069–2087. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Ding L, Jin R, Zhang H, Cheng L, Qin X, Chai J and Ye Q: Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140 kDa (RIP140) interact and cooperate in estrogen signaling. Int J Biochem Cell Biol. 41:1613–1618. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG and Goldberg GS: Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 99:1326–1333. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Koike K, Kasamatsu A, Iyoda M, Saito Y, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Tanzawa H and Uzawa K: High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer. Int J Oncol. 42:141–150. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Asada K, Ando T, Niwa T, Nanjo S, Watanabe N, Okochi-Takada E, Yoshida T, Miyamoto K, Enomoto S, Ichinose M, et al: FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene. 32:2140–2149. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Yu Y, Su Y, Shi L, Xie S, Hong Y, Liu X and Yin F: Low FHL1 expression indicates a good prognosis and drug sensitivity in ovarian cancer. Funct Integr Genomics. 24:252024. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Chen L, Zhu H, Li Y, Chen CC and Li M: FHL1 promotes glioblastoma aggressiveness through regulating EGFR expression. FEBS Lett. 595:85–98. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Wei X, Yuan Y, Sun Q, Zhan J, Zhang J, Tang Y, Li F, Ding L, Ye Q and Zhang H: Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter. J Cell Biol. 217:1335–1351. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shi MK, Xuan YL and He XF: FHL1 overexpression as a inhibitor of lung cancer cell invasion via increasing RhoGDIß mRNA expression. Cell J. 24:239–244. 2022.PubMed/NCBI | |
|
Matsumoto M, Kawakami K, Enokida H, Toki K, Matsuda R, Chiyomaru T, Nishiyama K, Kawahara K, Seki N and Nakagawa M: CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. Int J Mol Med. 26:241–247. 2010.PubMed/NCBI | |
|
Yi S, Luo M, Peng Y, Chen Y and Yu D: Anti-oncogenic mechanism of KLF17 in colon cancer by repressing cell migration and invasion via FHL1 upregulation. Chi J Physiol. 66:534–545. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Pei M, Li J, Wang Z, Liu S, Xiang L, Zhang J, Hong L, Lin J, Dai W, et al: Disruption of the CCDC43-FHL1 interaction triggers apoptosis in gastric cancer cells. Exp Cell Res. 415:1131072022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Lu J, Dou J, Lv Z, Qin XI and Lin J: FHL1 and Smad4 synergistically inhibit vascular endothelial growth factor expression. Mol Med Rep. 7:649–653. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Niu C, Liang C, Guo J, Cheng L, Zhang H, Qin X, Zhang Q, Ding L, Yuan B, Xu X, et al: Downregulation and growth inhibitory role of FHL1 in lung cancer. Int J Cancer. 130:2549–2556. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L, Niu C, Zheng Y, Xiong Z, Liu Y, Lin J, Sun H, Huang K, Yang W, Li X and Ye Q: FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth. J Cell Mol Med. 15:72–85. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Li J, Chen Z, Jiang K, Yang K, Huang F, Huang A, Zhang X, Zhang J and Wang H: VE-822 upregulates the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the progression of lung adenocarcinoma. Cell Oncol. 46:1001–1014. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lin J, Qin X, Zhu Z, Mu J, Zhu L, Wu K, Jiao H, Xu X and Ye Q: FHL family members suppress vascular endothelial growth factor expression through blockade of dimerization of HIF1α and HIF1β. IUBMB Life. 64:921–930. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Li H, Guo M, Zhang J, Zhang G, Sun N, Feng Y, Cui W and Xu F: FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma. Immunotherapy. 15:235–252. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, Zhang H, Lin J, et al: Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β-like signaling pathway. J Clin Invest. 119:349–361. 2009.PubMed/NCBI | |
|
Chen J, Zeng C, Jin J, Zhang P, Zhang Y, Zhang H, Li Y and Guan H: Overexpression of FHL1 suppresses papillary thyroid cancer proliferation and progression via inhibiting Wnt/β-catenin pathway. Endocrine. 85:238–249. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Fan Z, Liang C, Li L, Wang L, Liang Y, Wu J, Chang S, Yan Z, Lv Z, et al: A signature motif in LIM proteins mediates binding to checkpoint proteins and increases tumour radiosensitivity. Nat Commun. 8:140592017. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Y, Xu M, Cui Z, Yang Z, Zhang Z, Yin X, Huang X, Zhou M, Wang X and Chen C: Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia. EBioMedicine. 52:1026642020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Yan Y, Liu Y, Yi Q and Xu Z: Tabersonine enhances olaparib sensitivity through FHL1-Mediated Epithelial-mesenchymal transition in an ovarian tumor. J Nat Prod. 87:837–848. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Meng J, Chen X, Wang F and Han Z: Long non-coding RNA Small Nucleolar RNA Host Gene 4 ameliorates cigarette Smoke-induced proliferation, apoptosis, inflammation, and airway remodeling in alveolar epithelial cells through the modulation of the mitogen-activated protein kinase signaling pathway via the microRNA-409-3p/Four and a Half LIM Domains 1 axis. Eur J Med Res. 29:3092024. View Article : Google Scholar : PubMed/NCBI | |
|
Ding J, Cong YF and Liu B: Aberrant protein turn-over associated with myofibrillar disorganization in FHL1 knockout mice. Front Genet. 9:2732018. View Article : Google Scholar : PubMed/NCBI | |
|
Wong CH, Fung YW, Ng EK, Lee SM, Waye MM and Tsui SK: LIM domain protein FHL1B interacts with PP2A catalytic β subunit-A novel cell cycle regulatory pathway. FEBS Lett. 584:4511–4516. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Zhao K, Du Z, Chen Y, Zhang F, Jiang W, Zheng J, Wu X, Shen C and Xiao X: Systemic effect of FHL1 on neuromuscular junction and myotube formation via insulin-like growth factor and myostatin signaling pathways. Biochem Biophys Res Commun. 537:125–131. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schreckenbach T, Henn W, Kress W, Roos A, Maschke M, Feiden W, Dillmann U, Schulz JB, Weis J and Claeys KG: Novel FHL1 mutation in a family with reducing body myopathy. Muscle Nerve. 47:127–134. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Peters S: Electrocardiographic analysis in unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in FHL1. Int J Cardiol. 214:1362016. View Article : Google Scholar : PubMed/NCBI | |
|
Luo YB, Peng Y, Lu Y, Li Q, Duan H, Bi F and Yang H: Expanding the Clinico-genetic spectrum of myofibrillar myopathy: Experience from a Chinese neuromuscular center. Front Neurol. 11:10142020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Z, Zhu Y, Liu X, Zhang W, Liu J, Wu S, Xiao J, Yuan Y and Wang Z: FHL1-related clinical, muscle MRI and genetic features in six Chinese patients with reducing body myopathy. J Hum Genet. 64:919–926. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sepp R, Hategan L, Csányi B, Borbás J, Tringer A, Pálinkás ED, Nagy V, Takács H, Latinovics D, Nyolczas N, et al: The genetic architecture of hypertrophic cardiomyopathy in hungary: Analysis of 242 patients with a panel of 98 genes. Diagnostics (Basel). 12:11322022. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Y, Ban R, Qiao L, Chen J, Liu M, Liu J and Shi Q: Identification of novel FHL1 mutations associated with X-linked scapuloperoneal myopathy in unrelated Chinese patients. J Hum Genet. 68:477–484. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF and Prchal JT: Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 101:3294–3301. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Feng F, Yang P, Li Z, You J, Xie W, Gao X and Yang J: Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell. Int J Biochem Cell Biol. 44:320–326. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng Y, Zeng D, Qi X, Wang H, Wang X, Dai X and Qu L: FHL1: A novel diagnostic marker for papillary thyroid carcinoma. Pathol Int. 74:520–529. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Balraj A, Muthamilselvan S, Raja R and Palaniappan A: PRADclass: Hybrid Gleason grade-informed computational strategy identifies consensus biomarker features predictive of aggressive prostate adenocarcinoma. Technol Cancer Res Treat. 23:153303382312223892024. View Article : Google Scholar : PubMed/NCBI | |
|
Cai Y, Xia L, Zhu H, Cheng H, Tian Y, Sun L, Wang J, Lu N, Wang J and Chen Y: MiR-3682-3p promotes esophageal cancer progression by targeting FHL1 and activating the Wnt/β-catenin signaling pathway. Cell Signal. 119:1111552024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao JL, Liang SQ, Fu W, Zhu BK, Li SZ, Han H and Qin HY: The LIM domain protein FHL1C interacts with tight junction protein ZO-1 contributing to the epithelial-mesenchymal transition (EMT) of a breast adenocarcinoma cell line. Gene. 542:182–189. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dai J, Yu X, Han Y, Chai L, Liao Y, Zhong P, Xie R, Sun X, Huang Q and Wang J: TMT-labeling proteomics of papillary thyroid carcinoma reveal invasive biomarkers. J Cancer. 11:6122–6132. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fu W, Wang K, Zhao JL, Yu HC, Li SZ, Lin Y, Liang L, Huang SY, Liang YM, Han H and Qin HY: FHL1C induces apoptosis in notch1-dependent T-ALL cells through an interaction with RBP-J. BMC Cancer. 14:4632014. View Article : Google Scholar : PubMed/NCBI |
